期刊文献+

抗血小板治疗对急性心肌梗死合并慢性肾病患者血小板功能的影响 被引量:7

Effects of chronic kidney disease on platelet response to antiplatelet therapy in acute myocardial infarction patients
原文传递
导出
摘要 目的探讨双联抗血小板治疗对急性心肌梗死合并慢性肾病患者血小板聚集功能的影响。方法回顾分析2011年9月至2012年6月,195例植入药物洗脱支架的急性心肌梗死住院患者。其中非慢性肾病组133例,慢性肾病组62例,所有患者在服用氯吡格雷300mg和阿司匹林300mg治疗24h后,测定二磷酸腺苷诱导的血小板聚集率,比较其差异。血小板聚集率〉55%定义为血小板高反应性。结果与非慢性肾病组相比,慢性肾病组糖尿病发生率[24.8%(33/133)比43.5%(27/62),P=0.01],贫血发生率[5.3%(7/133)比16.1%(10/62),P=0.03)及血小板高反应性比例增高(28.6%(38/133)比45.2%(28/62),P=0.03]。多因素Logistic分析提示慢性肾病,糖尿病是血小板高反应发生的独立预测因素。慢性肾病组血小板聚集率较非慢性肾病组明显高(65.1%±10.2%比45.3%±7.8%,P〈0.01)。慢性肾病组及非慢性肾病组在使用双联血小板治疗前血小板聚集率无差异(79.2%±7.6%比78.4%±8.2%,P=0.51),而抗血小板治疗后,慢性肾病组血小板聚集率较非慢性肾病组明显高(63.2%±8.6%比43.2%±.2%,P〈0.01)。结论慢性肾病是急性心肌梗死患者血小板高反应性的影响因素,但其临床意义还需进一步研究证实。 Objective To elucidate the effects of dual antiplatelet therapy on platelet response in acute myocardial infarction patients with chronic kidney disease. Methods From September 2011 to June 2012, a total of 195 acute myocardial infarction patients with drug eluting stent implanting were enrolled. Among them, 133 cases had normal renal function and 62 cases suffered chronic kidney disease (CKD). Platelet reactivity was examined after clopidogrel 300 mg and aspirin 300 mg treatment for 24 h. High on treatment platelet reactivity (HPR) was defined as 〉 55% for light transmission aggreometry. Results The CKD patients had a higher incidence of diabetes mellitus (43.5% (27/62) vs 24. 8% (33/133), P = 0.01 ), anemia ( 16. 1% (10/62) vs 5.3 % (7/133), P = 0. 03) and high on treatment platelet reactivity (45.2% (28/62) vs 28. 6% ( 38/133 ), P = 0. 03 ) than those with normal kidney function. Logistic regression analyses showed that CKD and diabetes mellitus were independent predictors of HPR. Prevalence of HPR was higher in CKD patients than normal kidney function patients(65.1% ± 10. 2% vs 45.3% ± 7.8%, P 〈 0. 01 ). In subgroup analysis, testing was done before and after antiplatelet treatment. At baseline, no differences existed in platelet aggregation. However, absolute decrease in reactivity after antiplatelet treatment was significantly less in CKD patients than those with normal kidney function(63. 2% ± 8. 6% vs 43.2% ± 5.2%, P 〈 0.01 ). Conclusion CKD is an important contributor to apparent HPR.
出处 《中华医学杂志》 CAS CSCD 北大核心 2012年第38期2674-2676,共3页 National Medical Journal of China
基金 国家“十二五”攻关课题资助(2011BAI11B07)
关键词 心肌梗死 肾病 血小板聚集 Myocardial infarction Nephrosis Platelet aggregation
  • 相关文献

参考文献9

  • 1Palmer SC,Di Micco L, Razavian M, et al. Effects of antiplatelettherapy on mortality and cardiovascular and bleeding outcomes inpersons with chronic kidney disease : a systematic review and meta-analysis. Ann Intern Med,2012, 156:445459.
  • 2Ahn SG, Lee SH, Yoon JH, et al. Different prognosticsignificance of high on-treatment platelet reactivity as assessed bythe VerifyNow P2Y12 assay after coronary stenting in patients withand without acute myocardial infarction. JACC Cardiovasc Interv,2012,5 :259-267.
  • 3关绍义,韩雅玲,李毅,郭亮,杨柏松,王守力,荆全民,王效增,马颖艳,刘晓东.强化抗血小板治疗对冠状动脉支架术后血小板高反应性的影响[J].中华心血管病杂志,2012,40(1):25-29. 被引量:16
  • 4Levey AS, Coresh J, Balk E, et al. National Kidney Foundationpractice guidelines for chronic kidney disease : evaluation,classification, and stratification. Ann Intern Med, 2003,139:137-147.
  • 5Derry S, Loke YK. Risk of gastrointestinal haemorrhage with longterm use of aspirin: meta-analysis. BMJ,2000,321 : 1183-1187.
  • 6Remuzzi G. Bleeding in renal failure. Lancet, 1988, 1 : 1205-1208.
  • 7Angiolillo DJ, Bernardo E, Capodanno D, et al. Impact of chronickidney disease on platelet function profiles in diabetes mellituspatients with coronary artery disease taking dual antiplatelettherapy. J Am Coll Cardiol,2010,55 : 1139-1146.
  • 8Price MJ, Angiolillo DJ, Teirstein PS,et al. Platelet reactivityand cardiovascular outcomes after percutaneous coronaryintervention : a time-dependent analysis of the GaugingResponsiveness with a VerifyNow P2Y12 assay: Impact onThrombosis and Safety ( GRAVITAS) trial. Circulation, 2011,124:1132-1137.
  • 9Woo JS, Kim W, Lee SR,et al. Platelet reactivity in patients withchronic kidney disease receiving adjunctive cilostazol comparedwith a high-maintenance dose of clopidogrel ; results of the effect ofplatelet inhibition according to clopidogrel dose in patients withchronic kidney disease ( PIANO-2 CKD) randomized study. AmHeart J, 2011,162:1018-1025.

二级参考文献16

  • 1Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation, 2003, 107 : 2908- 2913.
  • 2Gurbel PA, Samara WM, Bliden KP. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets ,2004,15 : 95-99.
  • 3Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost,2006, 4:542-549.
  • 4Mehilli J, Pache J, Abdel-Wahab M, et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG) : a randomised controlled superiority trial. Lancet,2011,378:1071- 1078.
  • 5Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet,2001,358:527-533.
  • 6Gurbel PA, Becker RC, Mann KG, et al. Platelet function I- monitoring in patients with coronary artery disease. J Am Coil Cardiol,2007,50 : 1822-1834.
  • 7Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA, 2010, 303 : 754- 762.
  • 8Boneilo L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coil Cardiol,2010, 56:919-933.
  • 9Geisler T, Grass D, Bigalke B, et al. The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. J Thromb Haemost,2008,6:54-61.
  • 10Mehta SR, Bassand JP, Chrolavicius S, et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J,2008,156: 1080-1088.

共引文献15

同被引文献65

引证文献7

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部